Latest news with #Clinical
Yahoo
a day ago
- Business
- Yahoo
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035" report has been added to world revenue for the AI-Enabled Drug Discovery and Clinical Trials Market will surpass US$3.00 billion in 2025 with strong revenue growth projected through to 2035. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new Drug Development Timelines and Cost Efficiency Driving Market GrowthKey drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth. However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these and Data Integration Challenges to Hamper Market GrowthWhile the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical Questions Answered How is the AI-enabled drug discovery and clinical trials market evolving? What is driving and restraining the AI-enabled drug discovery and clinical trials market? How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035? How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035? What will be the main driver for the overall market from 2025 to 2035? Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035? Who are the leading players and what are their prospects over the forecast period? What are the AI-enabled drug discovery and clinical trials projects for these leading companies? How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years? Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market? Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market? What are the best investment options for new product and service lines? What are the key prospects for moving companies into a new growth path and C-suite? Recent Developments On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets. On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs. On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes. Leading Companies Profiled AiCure Aitia Atomwise Inc. BenevolentAI Insilico Medicine PathAI, Inc. Recursion Saama Technologies Schroedinger, Inc. Tempus Inc. Key Topics Covered: 1 Report Overview1.1 Objectives of the Study1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market1.3 What This Report Delivers1.4 Why You Should Read This Report1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report for?1.7 Methodology1.8 Frequently Asked Questions (FAQs)1.9 Associated Reports1.10 About the Publisher2 Executive Summary3 Market Overview3.1 Key Findings3.2 Market Dynamics3.3 Impact Analysis3.3.1 Market Driving Factors3.3.1.1 Growing Focus on Personalized Medicine3.3.1.2 Advancements in Technology3.3.1.3 Growing Adoption of AI in Healthcare3.3.2 Market Restraining Factors3.3.2.1 Limited Data Availability and Quality3.3.2.2 Integration with Existing Infrastructure3.3.2.3 Concerns over Data Privacy and Security3.3.3 Market Opportunities3.3.3.1 Improved Patient Outcomes3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials3.3.3.3 Growing Collaborations and Partnerships3.4 Regulatory Framework3.5 Emerging Markets and Megatrends3.6 Porter's Five Forces Analysis3.7 PEST Analysis4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component4.1 Key Findings4.2 Component Segment: Market Attractiveness Index4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component4.4 Services4.4.1 Market Size by Region, 2025-2035 (US$ Million)4.4.2 Market Share by Region, 2025 & 2035 (%)4.5 Software Solutions5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application5.1 Key Findings5.2 Application Segment: Market Attractiveness Index5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application5.4 Clinical Trials5.4.1 Market Size by Region, 2025-2035 (US$ Million)5.4.2 Market Share by Region, 2025 & 2035 (%)5.5 Drug Design5.6 Data Aggregation and Analysis5.7 Drug Characterization5.8 Biomarker Research5.9 Others6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area6.1 Key Findings6.2 Therapeutic Area Segment: Market Attractiveness Index6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area6.4 Oncology6.4.1 Market Size by Region, 2025-2035 (US$ Million)6.4.2 Market Share by Region, 2025 & 2035 (%)6.5 Cardiovascular Diseases6.6 Infectious Diseases6.7 Neurodegenerative Diseases6.8 Metabolic Diseases6.9 Immunological Disorders6.10 Others7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users7.1 Key Findings7.2 End-users Segment: Market Attractiveness Index7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users7.4 Pharmaceutical & Biopharmaceutical Companies7.4.1 Market Size by Region, 2025-2035 (US$ Million)7.4.2 Market Share by Region, 2025 & 2035 (%)7.5 Contract Research Organizations (CROs)7.6 Academic Institutes and Research Centre8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region8.1 Key Findings8.2 Regional Market Size Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News18
14-05-2025
- Health
- News18
Sleep Debt Passed Down: Are We Inheriting Exhaustion from Our Mothers?
Last Updated: Sleep patterns don't just shape our nights, they shape generations. Experts reveal how maternal sleep deprivation can impact a child's stress levels and emotional well-being. Sleep patterns and exhaustion don't just affect individuals—they can be passed down through generations. Maternal sleep habits have both biological and behavioral impacts on children. A sleep-deprived mother may unknowingly transmit stress to her children, leading to elevated cortisol levels. If she struggles to establish consistent sleep routines, it can delay the child's ability to self-regulate sleep. This disruption can also contribute to emotional and cognitive challenges, increasing the risk of anxiety and depression in children. Dr. Usha Gaddam, MBBS, DNB (Family Medicine), CCEBM-Diabetics (PHFT), CCMH-Hypertension (PHFT), PGDIP (Clinical Endocrinology and Diabetes, EACME), CCMD-Mental Health (PHFT), Apollo Clinic, Manikonda, explains, 'Generational sleep behavior plays a substantial role through both genetics and environment. Some children are genetically predisposed to be night owls or early birds. These patterns can be inherited, and cultural habits may further reinforce chronic sleep deprivation across generations." She further adds, 'Sleep disorders can affect both prenatal and postnatal development. Poor maternal sleep health increases the risk of gestational diabetes, preterm birth, low birth weight, and altered fetal brain development. It may also affect maternal hormone regulation, which directly influences fetal neurodevelopment. Mothers with sleep disorders often face difficulties in self-soothing, experience fragmented sleep, and may encounter long-term cognitive and behavioral challenges." To break the cycle of inherited sleep debt, both lifestyle and mindset changes are essential. Prioritizing maternal sleep is not a luxury—it's a necessity. Creating a supportive and restful environment for mothers can positively impact both their own health and their children's well-being. Create a calming sleep environment: Limit screen time, reduce noise, and keep the room dark and cool. Involve family members: Encourage partners and relatives to share childcare responsibilities to allow mothers to rest. Seek cognitive behavioral therapy (CBT-I): Especially useful for those struggling with chronic insomnia or anxiety. First Published: May 14, 2025, 10:34 IST
Yahoo
12-05-2025
- Health
- Yahoo
The Recalled Cookie Dough That Led To Illness In 30 States
If you don't have time to make cookies from scratch (even with the best chocolate chip cookie recipe out there), prepackaged dough is a great alternative. When it comes to popular varieties, Nestlé Toll House offers a selection of refrigerated dough products that not only save time in the kitchen but are also quite tasty where cookie quality is concerned. That doesn't mean the iconic brand hasn't experienced its share of troubles over the years, including an incident in 2009 that resulted in 77 people across 30 states falling ill (almost half of whom required hospitalization). Reports from the time indicated that flour within the ready-to-bake product was contaminated with bacteria called Shiga toxin–producing E. coli, which is a strain very likely to cause a severe E. coli infection. Investigators were unable to land on a definitive cause of illness among those affected, but the flour was suspicious because all other ingredients were deemed safe during the supplier investigation. E. coli infections often cause uncomfortable symptoms like stomach cramping and diarrhea, but 10 people affected by the 2009 outbreak developed hemolytic uremic syndrome, which can cause lasting kidney damage and other serious health effects. While the subsequent illness was quite severe, no deaths were reported as a result of this outbreak. Read more: Peanut Butter Brands Ranked Worst To Best The 2009 Nestlé Toll House cookie dough recall was unique because the way consumers used the product was a major factor in the illness that followed. According to the CDC, an investigation found that the majority of people who became ill consumed the contaminated dough raw, and as you hopefully know, eating raw cookie dough is a major no-no (despite how tempting it can be). In addition to health problems posed by raw eggs, raw flour can harbor harmful pathogens like E. coli, as illustrated by Nestlé Toll House's unfortunate situation. Prepackaged cookie doughs feature warnings about consuming the product raw and urge consumers to bake the product according to instructions prior to eating. However, a 2011 study published in Clinical Infectious Diseases had another recommendation in the wake of Nestlé Toll House's E. coli outbreak. After investigating the incident, researchers suggested that prepackaged doughs should be reformulated so that they can be consumed raw without issue. In this case, replacing raw flour with a heat-treated variety can prevent bacterial infections. Similarly, recipes must contain pasteurized eggs, which also undergo a heat-treating process. Worth noting is that Nestlé Toll House has been embroiled in other cookie dough recalls since the 2009 incident, including a 2022 recall that involved plastic contamination. Read the original article on Mashed.
Time of India
09-05-2025
- Health
- Time of India
Vet warns pet owners after common dog behaviour linked to massive parasite inside woman's body
What does the doctor say? Where is this parasite found? How to avoid this? How serious can it turn for humans A case from Tunisia has reignited an important health conversation about the hidden dangers of a common behaviour many pet owners find endearing—letting their dogs lick their faces. While millions of dog lovers share affectionate moments with their furry companions, experts are warning that this harmless gesture could, in rare cases, open the door to a potentially life-threatening recently discovered a massive cyst, double the size of a tennis ball, in the pelvis of a 26-year-old woman who was 20 weeks pregnant. The woman had endured months of abdominal pain before being rushed to the hospital, where scans revealed a hydatid cyst—a growth caused by a tapeworm infection. The condition, known as cystic echinococcosis, is caused by the Echinococcus granulosus tapeworm, most commonly transmitted through dog case was detailed in the Open Journal of Clinical & Medical Case Reports under the title "Omental hydatid cyst in pregnant women: A rare localization." The patient was from Tunisia, where the parasite is considered endemic. Researchers noted the woman's condition was rare and dangerous, especially during pregnancy, but she was treated the exact source of the woman's infection was not confirmed, the case has raised concerns among veterinarians, who are urging dog owners to be mindful of certain health risks. Dr. Aimee Warner, a veterinarian at pet insurance company Waggel, noted that letting dogs lick faces, particularly near the mouth or eyes, can pose hygiene humans don't become infected by adult tapeworms living in a dog's body, they can inadvertently ingest the parasite's eggs through faecal contamination. If a dog has traces of faeces on its mouth or fur and then licks a person, there is a small but possible risk of parasite thrives in areas where livestock are raised, and dogs may scavenge on infected animal remains, which contain larvae. Once ingested, the larvae mature into tapeworms in the dog's intestines. The eggs are then shed in the animal's stool, potentially contaminating the environment and putting humans at per the vet, regular deworming of dogs and practising good hygiene, especially after handling pets or letting them near the face, can significantly reduce the condition is extremely serious in humans, often impacting the liver, lungs, or other organs. In this particular case, the cyst formed in the omentum (a fold of tissue in the abdomen), which is an uncommon site of infection. If left untreated, hydatid cysts can grow and rupture, leading to life-threatening complications. Especially in vulnerable groups like pregnant women, early detection and surgical intervention may be the only way to avoid severe consequences.
Yahoo
29-04-2025
- Health
- Yahoo
New data from J&J's bladder cancer drug-device trial strengthens support for NDA
Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Data, announced during the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology plenary session at the American Urological Association (AUA) Annual Meeting 2025, showed a high response rate in one of the cohorts from the Phase IIb SunRISe-1 trial (NCT04640623). J&J announced new data from both cohort two and cohort four at the conference. TAR-200, trademarked as GemRIS, is a drug-device combination product that continuously delivers gemcitabine chemotherapy directly to the bladder over a week. It can be inserted without the need for anaesthesia or sedation. J&J acquired TAR-200 and the drug delivery technology during its purchase of Taris Biomedical in 2019. In the new data from cohort two, which enrolled 85 BCG-unresponsive NMIBC patients with carcinoma in situ, 82.4% achieved a complete response (CR), with this translating into sustained disease control, with 52.9% of responders maintaining CR at one year. In the same cohort, the median duration of response (DOR) was 25.8 months and at 12 months, 86.6% of patients who responded to treatment remained cystectomy-free. Meanwhile, patients in cohort four, 52 HR-NMIBC patients with papillary disease-only, 85.3% and 81.1% disease-free survival (DFS) rates at six and nine months. Also, 94.2% of patients avoided cystectomy at a median follow-up of 12.8 months. J&J also reported progression-free (PFS) and overall survival (OS) rates of 95.6% and 98% at nine months, respectively. In both cohorts, TAR-200, the treatment was well-tolerated, with most adverse events (AEs) being mild urinary symptoms. These findings indicate that TAR-200 offers a highly effective and durable treatment option for patients with certain types of BCG-unresponsive HR-NMIBC. Most treatment-related AEs were mild and manageable. Between both cohorts, seven patients discontinued treatment due to treatment-related AEs, and there were no treatment-related deaths. Disease area leader of bladder cancer for J&J Innovative Medicine, Dr. Christopher Cutie, said: 'Bladder cancer is one of the ten most common cancers worldwide, yet treatment options have remained largely unchanged for over 40 years, leaving patients with few choices if initial BCG therapy does not work. TAR-200 is designed to allow for sustained delivery of medication directly into the bladder through a brief and routine procedure, which benefits patients. These data now show patients can remain cancer-free for a meaningful period of time, marking a significant step forward for those facing this challenging disease.' The new data, announced on Saturday 26 April comes after J&J filed a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TAR-200 in January 2025 based on previous data announced from the SunRISe-1 trial. The application is for the use of TAR-200 in NMIBC patients with carcinoma in situ who are BCG-unresponsive, with or without papillary tumours. This submission is being reviewed through the Real-Time Oncology Review (RTOR) programme, which allows the FDA to review data before the complete application is formally submitted. Earlier results from cohort two were presented at the European Society of Medical Oncology (ESMO) Congress 2024 and the AUA 2024 Meeting. TAR-200 did not, however, show benefit in a Phase III trial in patients with muscle-invasive bladder cancer (MIBC) not undergoing radical cystectomy. The Phase III SunRISe-2 study (NCT04658862) was terminated by J&J after an independent data monitoring committee said the trial was unlikely to meet its primary endpoint of bladder intact-event free survival (BI-EFS). The Phase II SunRISe-4 trial, also in patients with MIBC, is ongoing. The SunRISe-1 trial is ongoing, and TAR-200 is also being investigated in NMIBC in two Phase III studies, SunRISe-3 (NCT05714202) and SunRISe-5 (NCT06211764). Also at the AUA Annual Meeting 2025, Pfizer presented positive data from a Phase III trial of sasanlimab and BCG, with the combination therapy improving event-free survival (EFS) in BCG-naïve high-risk NMIBC patients compared to subjects who were only given BCG, meeting the trial's primary endpoint. "New data from J&J's bladder cancer drug-device trial strengthens support for NDA" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
